Invest1 distinct publisher2 min readPublished
Bank of America kept its buy and $810 target through the Oakland youth-harm trial, calling it one data point in years of litigation. Its own 16x 2027 multiple asks for more than patience.
The Investor · Invest desk

Compiled by The InvestorSomething wrong?How this is made
Run the bank's own inputs backwards and the target looks like two calls stapled together. A share price around $560 at roughly 16 times estimated 2027 earnings puts that 2027 figure near $35 [2][3][18]. Reaching $810 means paying about 23 times the same $35 [19], or holding the multiple at 16 and finding 2027 earnings nearer $50 [20]. The litigation argument only works on the first of those. The second rests on the AI capacity spending that has been its own source of investor unease all year, alongside the question of when it returns anything [2][22].
Most of what Bank of America offers on the trial itself is procedural, and procedure is a discount-rate argument. The Oakland jury is advisory, so the judge can accept or reject what it concludes [7]. Excessive damages can be trimmed by remittitur, awards can be overturned on appeal, and the fight could run as far as the Supreme Court [10]. Each step pushes any payment further to the right, which is the polite way of saying it shrinks in present value before it is ever written. Jim Cramer's version is the same trade in plainer language: Meta keeps appealing and holders keep waiting [17].
The judge's housekeeping cuts against the bears more than the headlines suggest. Infinite scroll and autoplay are already dismissed; what is left in front of the jury is multiple accounts, appearance-altering filters and tools for managing time spent [8]. Those are narrower mechanics, so a plaintiff win on this set compels less than a win on the original set would have. Bank of America also argues causation is still a hurdle, because plaintiffs have to tie specific platform features to specific youth harm [9]. Meta's chosen ground is immunity under Section 230, and the bank concedes the case may test whether that provision reaches design decisions at all [16].
None of that stops the noise. Zuckerberg and other employees are expected to testify, and the bank's own note allows that this verdict sets the tone for the cases queued behind it [5].
Ranked by verification strength, evidence, and original report placement.
Bank of America wrote to clients on Monday that while Meta stock is down on California trial headlines, "the current bellwether trial outcome will represent only one data point in a multi-jurisdictional litigation process that will take many years to resolve."
Bank of America kept its buy rating on Meta, citing a "compelling valuation" of around 16 times estimated 2027 earnings due to "growing AI capacity assets."
Bank of America maintained a $810 price target on Meta, implying nearly 45% upside from current levels around $560.
Meta faces a federal lawsuit brought by 29 state attorneys general; the trial got underway in an Oakland court last week and could result in billions of dollars in damages and forced remedies that could lead to an overhaul of Facebook and Instagram.
Testimony from CEO Mark Zuckerberg and other company employees is expected, and the outcome is consequential because it could set the tone for other pending cases across the country.
Meta shares are down 26% in 2026, making it one of the worst-performing mega-cap tech stocks.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
One publisher relaying analyst notes
The cluster rests on a single CNBC Investing Club article that quotes BofA and Mizuho notes secondhand; the notes, court filings, and trial record are not supplied. Verifiable market and procedural facts (target, drawdown, advisory jury, narrowed claims, two March verdicts) are specific and internally consistent, but the valuation math is only supported by inputs the article states in passing and no second publisher corroborates any figure.
Platform scale disclosed, remedy impact unmeasured
The supplied material documents the installed base and revenue dependence that any remedy would touch — three billion monthly active users and over 90% ad revenue — plus a nascent compute-resale effort. What it does not document is any adopted change: no engagement feature has actually been altered, no settlement terms exist, and the article concedes remedy talk is 'all speculation at this point.'
Target framing outruns its own multiple
The bull case is presented as a patience trade — hold through years of litigation at a 'compelling' 16x 2027 earnings — but the maintained $810 target is roughly 23x the earnings those same inputs imply, meaning it requires multiple expansion or about $50 of 2027 earnings. Litigation risk is also treated asymmetrically: procedural offramps are enumerated while the two March verdicts and Mizuho's tens-of-billions scenario are noted without quantified exposure. The overstatement is in framing rather than in the underlying facts, which are specific and mostly checkable.
Sell-side ratings plus a disclosed long position
Every substantive judgment in the cluster comes from parties with position exposure: two sell-side firms maintaining published ratings and scenarios, and a CNBC Investing Club writeup whose commentator's charitable trust is long Meta, disclosed in the article. Mizuho's more bearish read provides some internal counterweight, but no disinterested legal or plaintiff-side voice appears.
Specific but single-sourced and interest-laden
Claims are dated, attributed, and unusually specific, and the derived arithmetic follows directly from figures the article states. Confidence is capped by having one publisher, no access to the underlying notes or docket, and an evidence base composed entirely of positioned commentary about a trial whose outcome is unresolved.
invest
Meta's Oakland trial is the only one of three megacap legal fronts with a number attached1 distinct publisher
product
Meta's under-13 data practices go to a jury: 29 AGs, COPPA, and a porous age gate1 distinct publisher
invest
Meta's Pay Structure, Not Its Policy Page, Is What the States Put on the Stand1 distinct publisher
leadership
A safety engineer says he briefed Zuckerberg 100 times. The escalation trail is now evidence.1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 24, 2026